M.E. Allison & CO. Inc. Makes New $1.01 Million Investment in Johnson & Johnson (NYSE:JNJ)

M.E. Allison & CO. Inc. bought a new stake in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 6,999 shares of the company’s stock, valued at approximately $1,012,000. Johnson & Johnson accounts for 1.1% of M.E. Allison & CO. Inc.’s investment portfolio, making the stock its 23rd biggest holding.

Several other large investors have also modified their holdings of JNJ. IFS Advisors LLC raised its stake in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares in the last quarter. Highline Wealth Partners LLC purchased a new position in Johnson & Johnson in the third quarter worth $31,000. RPg Family Wealth Advisory LLC acquired a new stake in Johnson & Johnson in the third quarter valued at $35,000. Mowery & Schoenfeld Wealth Management LLC grew its stake in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares during the period. Finally, Activest Wealth Management purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at about $40,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.7 %

Shares of Johnson & Johnson stock opened at $148.10 on Wednesday. The firm has a market cap of $356.57 billion, a PE ratio of 21.43, a P/E/G ratio of 2.39 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The business’s fifty day moving average is $148.35 and its two-hundred day moving average is $156.11.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.35%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Insider Activity

In other news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent analyst reports. Citigroup lowered their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Royal Bank of Canada lifted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Guggenheim upped their target price on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Finally, Barclays dropped their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating for the company in a report on Tuesday. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $173.27.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.